Skip to main content

Table 2 Frequency of first-line chemotherapeutic regimens and incidence of AE-ILD during first-line chemotherapy

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

  Bev group (n = 17) Non-Bev group (n = 31)
Regimens N Incidence of AE N Incidence of AE
CDDP + PEM 4 0 7 1
CBDCA + PEM 10 0 15 4
PEM 1 0 3 1
CBDCA + PTX 2 0 6 1
Total treatments 17 0 31 7
PEM-containing regimens 15 0 25 6
  1. Data are expressed as number of patients. AE-ILD acute exacerbation of interstitial lung disease, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel